COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT VS OTHER AVAILABLE
Author(s)
Garita M1, Peralta M1, Muñoz-Louis R2
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2Hospital Docente Padre Billini, Ministerio de Salud, Santo Domingo, Dominican Republic
OBJECTIVES: Rheumatoid Arthritis (RA) affects approximately 0.4% of the Latin American population over 16 years of age. [1] Decreased pain and disability prevention may be possible with a early diagnosis and appropriate treatment. [2] The objective is to assess the cost-effectiveness (CE) of Etanercept in the treatment for moderate to severe RA, with previous antirheumatic drugs failure, in comparison with the rest of anti-TNF and IL-6 blockers available in Dominican Republic, from the healthcare payer’s perspective
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PMS34
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Musculoskeletal Disorders